Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38%
Key takeaways
- PFE If you ve spent any time reading about certain stocks, you ll have noticed that opinions among Wall Street analysts can vary widely.
- Here s one example: Pfizer (NYSE: PFE).
- Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need.
PFE If you ve spent any time reading about certain stocks, you ll have noticed that opinions among Wall Street analysts can vary widely. Because there s no way to definitively determine where a stock will be in the future, it s hard to know for sure that it s a buy, sell, or hold. It s the same with The Motley Fool: One of its writers might be very bullish on one stock, while her colleague is bearish. That s why it s good to read multiple opinions and think them through on your own.
Here s one example: Pfizer (NYSE: PFE). The MarketWatch website recently tracked 28 ratings for the stock: Nine Wall Street analysts said "buy," one said the stock was overweight (which essentially means it s a buy), 15 said "hold," and three said "sell." The consensus, then, was to hold.
Will AI create the world s first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »